Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (XBOT) a multicentre, open-label, randomised controlled trial.
Extended-release naltrexone (XR-NTX), an opioid antagonist, and sublingual buprenorphine-naloxone (BUP-NX), a partial opioid agonist, are pharmacologically and conceptually distinct interventions to prevent opioid relapse. We aimed to estimate the difference in opioid relapse-free survival between XR-NTX and BUP-NX. We initiated this 24 week, open-label, randomised controlled, comparative effectiveness trial at eight US community-based inpatient services and followed up participants as outpatients. Participants were 18 years or older, had Diagnostic and Statistical Manual of Mental Disorders-5 opioid use disorder, and had used non-prescribed opioids in the past 30 days. We stratified participants by treatment site and opioid use severity and used a web-based permuted block design with random equally weighted block sizes of four and six for randomisation (11) to receive XR-NTX or BUP-NX. XR-NTX was monthly intramuscular injections (Vivitrol Alkermes) and BUP-NX was daily self-administered buprenorphine-naloxone sublingual film (Suboxone Indivior). The primary outcome was opioid relapse-free survival during 24 weeks of outpatient treatment. Relapse was 4 consecutive weeks of any non-study opioid use by urine toxicology or self-report, or 7 consecutive days of self-reported use. This trial is registered with ClinicalTrials.gov, NCT02032433. Between Jan 30, 2014, and May 25, 2016, we randomly assigned 570 participants to receive XR-NTX (n283) or BUP-NX (n287). The last follow-up visit was Jan 31, 2017. As expected, XR-NTX had a substantial induction hurdle fewer participants successfully initiated XR-NTX (204 72% of 283) than BUP-NX (270 94% of 287 p<0·0001). Among all participants who were randomly assigned (intention-to-treat population, n570) 24 week relapse events were greater for XR-NTX (185 65% of 283) than for BUP-NX (163 57% of 287 hazard ratio HR 1·36, 95% CI 1·10-1·68), most or all of this difference accounted for by early relapse in nearly all (70 89% of 79) XR-NTX induction failures. Among participants successfully inducted (per-protocol population, n474), 24 week relapse events were similar across study groups (p0·44). Opioid-negative urine samples (p<0·0001) and opioid-abstinent days (p<0·0001) favoured BUP-NX compared with XR-NTX among the intention-to-treat population, but were similar across study groups among the per-protocol population. Self-reported opioid craving was initially less with XR-NTX than with BUP-NX (p0·0012), then converged by week 24 (p0·20). With the exception of mild-to-moderate XR-NTX injection site reactions, treatment-emergent adverse events including overdose did not differ between treatment groups. Five fatal overdoses occurred (two in the XR-NTX group and three in the BUP-NX group). In this population it is more difficult to initiate patients to XR-NTX than BUP-NX, and this negatively affected overall relapse. However, once initiated, both medications were equally safe and effective. Future work should focus on facilitating induction to XR-NTX and on improving treatment retention for both medications. NIDA Clinical Trials Network.